Holen Sie sich die Stockscreener-App
250.52
0.09%
-0.23
Handel nachbörslich:
249.60
-0.92
-0.37%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$250.75
Offen:
$249.23
24-Stunden-Volumen:
1.21M
Relative Volume:
1.13
Marktkapitalisierung:
$36.56B
Einnahmen:
$5.26B
Nettoeinkommen (Verlust:
$1.44B
KGV:
25.64
EPS:
9.7713
Netto-Cashflow:
$1.76B
1W Leistung:
+2.37%
1M Leistung:
-3.46%
6M Leistung:
+3.16%
1J Leistung:
+2.76%
1-Tages-Spanne:
$248.45
$251.57
1-Wochen-Bereich:
$241.81
$254.00
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
250.52 | 36.60B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
568.48 | 199.09B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
190.96 | 55.24B | 21.84B | 1.68B | 2.67B | 5.8322 |
|
ALC
Alcon Inc
|
76.25 | 37.63B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
WST
West Pharmaceutical Services Inc
|
273.99 | 19.50B | 2.96B | 487.70M | 344.00M | 6.6758 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Inc. Announces Change in Board Leadership - TipRanks
ResMed CFO Acquires Performance-Based Shares - TipRanks
ResMed Director Increases Stake with New Stock Acquisition - TipRanks
ResMed Inc. Expands Equity Incentive Plan with Additional Share Registration - MSN
IDEXX Laboratories Vs ResMed: Which Stock Could Rally? - Forbes
ResMed Inc. Expands Employee Stock Purchase Plan with New Share Registration - MSN
Swiss National Bank Boosts Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Acquired by Legal & General Group Plc - MarketBeat
Handelsbanken Fonder AB Cuts Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc RME Stock Analysis and ForecastMomentum Stock Picks & Minimal Capital Appreciation - earlytimes.in
ResMed Inc. $RMD Shares Purchased by Mediolanum International Funds Ltd - MarketBeat
Prudential PLC Sells 39,187 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Acquired by Empowered Funds LLC - MarketBeat
Ensign Peak Advisors Inc Reduces Position in ResMed Inc. $RMD - MarketBeat
Is ResMed's 10% Year-to-Date Gain Justified After Recent Industry Headlines? - Yahoo Finance
Martin Currie Ltd. Has $35.12 Million Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Acquired by Entropy Technologies LP - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Has $5.64 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc Updates Dividend Exchange Rate for CDI Holders - MSN
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know - Finviz
[Form 4] RESMED INC Insider Trading Activity - Stock Titan
[S-8] RESMED INC Employee Benefit Plan Registration | RMD SEC FilingForm S-8 - Stock Titan
Traders Buy Large Volume of Put Options on ResMed (NYSE:RMD) - MarketBeat
Will ResMed Inc. stock benefit from infrastructure spendingJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com
ResMed Inc. $RMD Shares Purchased by Vanguard Group Inc. - MarketBeat
Nomura Asset Management Co. Ltd. Purchases 2,186 Shares of ResMed Inc. $RMD - MarketBeat
Can ResMed Inc. stock withstand sector downturnsQuarterly Market Review & Long-Term Growth Portfolio Plans - newser.com
Will ResMed Inc. (RME) stock announce special dividendOptions Play & Consistent Profit Focused Trading Strategies - newser.com
ResMed Inc. (RMD) Announces Key Amendments to Incentive and Stoc - GuruFocus
ResMed Streamlines Governance at Annual Meeting - TipRanks
[8-K] RESMED INC Reports Material Event | RMD SEC FilingForm 8-K - Stock Titan
Should Strong Q1 Results and New Industry Trends Prompt Action From ResMed (RMD) Investors? - Sahm
July 2026 Options Now Available For ResMed (RMD) - Nasdaq
Is ResMed Inc. stock attractive for passive investorsWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
Are Wall Street Analysts Predicting ResMed Stock Will Climb or Sink? - MSN
Universal Beteiligungs und Servicegesellschaft mbH Has $23.87 Million Stock Position in ResMed Inc. $RMD - MarketBeat
Analysts Issue Forecasts for ResMed's Q2 Earnings (NYSE:RMD) - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock top growth indexes2025 Market Overview & Fast Moving Market Watchlists - newser.com
ResMed Inc Reports Change in Beneficial Ownership - MSN
What makes ResMed Inc. stock appealing to growth investors2025 Volatility Report & Daily Oversold Bounce Ideas - newser.com
ResMed Inc. $RMD Holdings Lifted by SG Americas Securities LLC - MarketBeat
Creative Planning Purchases 1,765 Shares of ResMed Inc. $RMD - MarketBeat
How strong is ResMed Inc. (Common Stock) (RMEA) stock earnings growth2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
Is ResMed Inc. (Common Stock) (RMEA) stock in buy zone after pullbackJuly 2025 Action & Weekly Setup with High ROI Potential - newser.com
Can ResMed Inc. stock hold up in economic slowdownTrade Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Is ResMed Inc. stock positioned for digital growth era2025 Analyst Calls & Long-Term Safe Investment Plans - newser.com
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
Can ResMed Inc. (Common Stock) (RMEA) stock attract analyst upgradesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Why analysts remain bullish on ResMed Inc. stockChart Signals & Fast Exit and Entry Trade Guides - newser.com
Is ResMed Inc. stock vulnerable to regulatory risksMarket Trend Summary & Daily Technical Forecast Reports - newser.com
How ResMed Inc. (RME) stock behaves in tightening cyclesStop Loss & AI Driven Price Forecasts - newser.com
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):